Symbolbild · KI-generiert
Sernova Biotherapeutics Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A Bio-hybrid Organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues and blood vessels to provide oxygen and nutrients to contained cells to restore or enhance the function of a compromised or explanted organ.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Sernova Biotherapeutics Inc. | SVA | TSX | 30 Mio. USD |
| BriaCell Therapeutics Corp. | BCT | TSX | 30 Mio. USD |
| NurExone Biologic Inc. | NRX | TSXV | 30 Mio. USD |
| Microbix Biosystems Inc. | MBX | TSX | 29 Mio. USD |
| Rockwell Medical Inc. | RMTI | NASDAQ | 28 Mio. USD |
| TempraMed Technologies Ltd. | VIVI | CSE | 27 Mio. USD |
| Nova Leap Health Corp. | NLH | TSXV | 27 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.